The evidence for systemic blood-marker changes from red light therapy is modest. Most red light therapy research is on local effects (skin, muscle, joint) rather than systemic biomarkers.
What the evidence supports (modestly):
- Systemic inflammation — some evidence for whole-body photobiomodulation reducing hs-CRP in specific patient populations (chronic pain, systemic inflammatory conditions). Not well-established for healthy adults.
- Improved sleep quality from red light exposure at appropriate times, which indirectly can lower inflammatory markers.
- Local skin effects — well-documented for red and near-infrared wavelengths (Wunsch & Matuschka, 2014; Ablon, 2018).
What the evidence does not support (yet):
- Meaningful improvements in HbA1c or fasting glucose from light therapy alone
- Direct effects on estradiol, vitamin D (a face-mask style device doesn't provide UV needed for vitamin D synthesis)
- Reduction in omega-3 deficiency (this requires dietary/supplement change)
- Claims of general "biological age" reversal from light therapy
The honest picture: red light therapy has real local skin effects and modest systemic anti-inflammatory effects at best. It's a reasonable adjunct to a well-managed skin longevity program — not a replacement for the biomarker-level interventions that actually move blood work (diet, sleep, sun protection, hormonal management, targeted supplementation).
Blood markers to actually track when trying interventions: hs-CRP, HbA1c, estradiol, vitamin D, omega-3 index. Five of the nine on the JenSkin panel.